Physiological Modeling of Responses to Upper Versus Lower Lobe Lung Volume Reduction in Homogeneous Emphysema by Arschang Valipour et al.
ORIGINAL RESEARCH ARTICLE
published: 01 October 2012
doi: 10.3389/fphys.2012.00387
Physiological modeling of responses to upper versus lower
lobe lung volume reduction in homogeneous emphysema
Arschang Valipour 1, Mordechai R. Kramer 2, Franz Stanzel 3, Axel Kempa3, Sherwin Asadi 1, Oren Fruchter 2,
Ralf Eberhardt 4, Felix J. Herth4 and Edward P. Ingenito5*
1 Department of Respiratory and Critical Care Medicine, Ludwig-Boltzmann-Institute for COPD, Otto Wagner Hospital, Vienna, Austria
2 Beilinson Hospital, Rabin Medical Center, Petah Tikva, Tel Aviv, Israel
3 Lungenklinik Hemer, Pneumologie – Thorakale Endoskope, Hemer, Germany
4 Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany
5 Brigham and Women’s Hospital, Boston, MA, USA
Edited by:
Ian M. Colrain, SRI International’s
Center for Health Sciences, USA
Reviewed by:
Joseph A. Fisher, University Health
Network, Canada
Norihiro Shinozuka, Chibaken
Saiseikai Narashino Hospital, Japan
*Correspondence:
Edward P. Ingenito, Pulmonary and
Critical Care Medicine, Brigham and
Women’s Hospital, Boston, MA
02115, USA.
e-mail: eingenito@partners.org
The polymer sealant is known
commercially as AeriSeal®
Emphysematous Lung Sealant.
www.clinicaltrials.gov registration
numbers for trials contributing to data
sets in this report: NCT01051258 and
NCT01181466.
Rationale: In clinical trials, homogeneous emphysema patients have responded well to
upper lobe volume reduction but not lower lobe volume reduction. Materials/Methods:To
understand the physiological basis for this observation, a computer model was developed
to simulate the effects of upper and lower lobe lung volume reduction on RV/TLC and lung
recoil in homogeneous emphysema. Results: Patients with homogeneous emphysema
received either upper or lower lobe volume reduction therapy based on findings of radionu-
cleotide scintigraphy scanning. CT analysis of lobar volumes showed that patients under-
going upper (n=18; −265 mL/site) and lower lobe treatment (LLT; n=11; −217 mL/site)
experienced similar reductions in lung volume. However, only upper lobe treatment
(ULT) improved FEV1 (+11.1±14.7 versus −4.4±15.8%) and RV/TLC (−5.4±8.1 versus
−2.4±8.6%). Model simulations provided an unexpected explanation for this response.
Increases in transpulmonary pressure subsequent to volume reduction increased RV/TLC
in upper lobe alveoli, while caudal shifts in airway closure decreased RV/TLC in lower
lobe alveoli. ULT, which eliminates apical alveoli with high RV/TLC values, lowers the aver-
age RV/TLC of the lung. Conversely, LLT, which eliminates caudal alveoli with low RV/TLC
values, has less effect. Conclusion: LLT in homogeneous emphysema is uniformly less
effective than ULT.
Keywords: physiological modeling of emphysema, lung volume reduction
INTRODUCTION
Surgical lung volume reduction (LVRS) in patients with homoge-
neous emphysema has been shown to improve physiology and
functional outcomes, although responses are generally smaller
than in patients with heterogeneous upper lobe disease (Weder
et al., 2009). Independent of the distribution of disease in any
given patient, LVRS generally involves resection of tissue in the
upper lobes due to limited surgical access to lower lobe sites
(DeCamp et al., 2008). AeriSeal® Emphysematous Lung Sealant
(ELS) is a novel endoscopic lung volume reduction (ELVR) treat-
ment shown to improve pulmonary function in patients with
advanced emphysema (Herth et al., 2011a). In contrast to LVRS,
ELVR therapies such as ELS allow physicians to access sites in
the lower lobes endoscopically, facilitating lower lobe treatment
(LLT).
While ELS improves lower lobe access, physiological benefit in
homogeneous emphysema patients has been limited almost exclu-
sively to those treated in the upper lobes. This study describes the
development of a physiological model that explains why patients
with advanced homogeneous emphysema who receive lower lobe
ELVR are less likely to benefit than those treated in the upper
lobes.
MATERIALS AND METHODS
STUDY SUBJECTS
Results for the subset of patients with advanced homogeneous
emphysema from two clinical trials of AeriSeal ELS treatment
(#NCT01051258 and #NCT01181466) are included in this report
(Herth et al., 2011a,b). Both trials were open-labeled and multi-
center, and were performed at four teaching hospitals in Germany,
one in France, one in Austria, and two in Israel. Studies were
approved by the Ethics Committee’s at all participating centers.
Written informed consent was obtained from all patients whose
data is included in this manuscript. Patient inclusion/exclusion
criteria are listed on www.clinicaltrials.gov.
Thirty patients with advanced homogeneous emphysema were
enrolled in study NCT01051258. All participants were treated at
two subsegmental sites unilaterally. Eighteen received upper lobe
treatment (ULT), and 12 LLT. Three month follow-up data, includ-
ing physiology and CT imaging, is available for 29 patients, 18 in
the ULT group and 11 in the LLT group.
Ten patients with advanced homogeneous emphysema were
included in study NCT011811466, which was initiated following
completion and analysis of data from study NCT01051258. All
patients in this second study received ULT at four subsegments,
www.frontiersin.org October 2012 | Volume 3 | Article 387 | 1
Valipour et al. Lung volume reduction in homogeneous emphysema
two in each upper lobe. Three month follow-up data including
physiology and CT imaging is available for nine patients.
DESIGN
Screening evaluations in both studies included pulmonary func-
tion tests (spirometry, plethysmography, and single breath diffus-
ing capacity), functional and quality of life assessments, chest CT
scan performed at full inspiration, and quantitative scintigraphy
perfusion scanning.
METHODS – IMAGE ACQUISITION AND ANALYSIS
CT images were generated using a standardized acquisi-
tion/reconstruction algorithm (spiral acquisition using a multi-
detector CT scanner with 0.75–1 mm collimation, pitch of 1, and
0.5 mm overlap). Computer analysis of baseline and post treat-
ment images was performed using commercially available software
(VIDA Diagnostics Pulmonary Workstation Plus Software, Iowa
City, IA, USA) to confirm homogeneous emphysema among study
patients, and to measure lobar volume reduction in response to
ELS treatment at 3 month follow-up. Disease heterogeneity was
evaluated quantitatively, and expressed as a Heterogeneity Index
(HI), defined as the ratio of % of voxels with a density<−910 HU
in the upper lobes (right upper+ left upper) to that in the lower
lobes (right lower+ left lower). Patients were designated as having
homogeneous disease if their HI was between 0.85 and 1.15. ELS
treatment sites were chosen based upon quantitative scintigraphy
perfusion scanning, targeting regions with low perfusion.
Baseline and 3 month follow-up physiology and radiology
results were used to assess disease distribution, lobar volume
reduction, and corresponding physiological responses to treat-
ment.
METHODS – COMPUTER MODELING
A computer model was developed to simulate the effects of tar-
geted volume reduction on gas trapping. The model can be used
to examine physiological response patterns in either heteroge-
neous or homogeneous disease but was used solely for simulating
homogeneous physiology in this analysis.
The lung was modeled as a collection of discrete alveoli
arranged in layers from diaphragm to apex. The healthy lung
was considered to have 300 million alveoli. Alveolar number (n)
and size were independent simulation parameters. Each alveolus
was modeled as having a constitutive pressure-volume relation-
ship of the form V = Vmax −Ae−kPtp(z), where V equals alveolar
volume, P tp(z) transpulmonary pressure as a function of cranio-
caudal location (z),A=Vmax−Vmin,Vmax equals alveolar volume
at “infinite” inflation pressure,Vmin alveolar volume at 0 inflation
pressure, and k the “shape factor” that determines the curvature of
the exponential relationship between pressure and volume (Ingen-
ito et al., 2003). Vmax, Vmin, k, and P tm′ are user-specified model
parameters, and can vary from region to region to simulate het-
erogeneity in tissue damage. Since each alveolus is considered
separately, Vmax, Vmin, k, and P tm′ could be considered larger
for upper lobe alveoli than lower lobe alveoli when simulating
upper lobe predominant emphysema. Conversely, the opposite
would apply when simulating lower lobe predominant emphy-
sema. However, for the simulations performed in this analysis of
homogeneous emphysema, values of Vmax,Vmin, k, and P tm′ were
considered as independent of location within the lung. P tp varies
as a function of distance (z) from the lung apex, and is equal
to P tp(0)−ρlung(z)× g, where P tp(0) equals P tp at the apex, lung
tissue density (ρlung) is set equal to 25% of water density, and
g is gravitational acceleration. Calculations were performed in
Microsoft Excel® to predict: (1) alveolar volumes at full infla-
tion (Total Lung Capacity=TLC) and full deflation (Residual
Volume=RV) as a function of cranio-caudal position within the
lung; (2) regional alveolar RV/TLC ratios; and (3) overall RV, TLC,
and RV/TLC values for the entire lung by integrating results across
all alveoli.
Emphysema was modeled by reducing the total number of
alveoli (n), increasing the size of alveoli (i.e., increasing Vmax
and Vmin), increasing alveolar gas trapping (i.e., increasing
Vmin/Vmax), increasing k (to simulate iso-volume loss of recoil),
and increasing P tm′ (to simulate premature airway closure and
gas trapping due to loss of airway tethering). For the current
simulations of homogeneous emphysema, P tm′ was considered
invariant as a function of distance from the lung apex (i.e.,
P tm′ is constant throughout the lung), while P tp(z) decreases
monotonically from apex-to-base in the gravitational field. There-
fore, near the lung apex P tp exceeds P tm′ and airways remain
opened. However, near the lung base, P tm′ can exceed P tp, and
airways can close, trapping gas behind them. The location at
which P tp= P tm′ denotes the position (z) at which airway clo-
sure occurs. For alveoli located above this point, volume is
determined by the equation, V = Vmax − Ae−kPtp(z), and
those alveoli nearer the lung apex are more inflated than alve-
oli nearer the diaphragm. Below the point at which P tp= P tm′ ,
alveolar volumes are considered invariant with position (z),
and are set equal to the amount of trapped gas at airway
closure.
The effects of ELS volume reduction therapy were simulated by:
(1) reducing the number of alveoli at specific target sites (i.e., either
upper or lower lung fields) to reflect elimination of alveolar units;
(2) decreasing P tm′ to reflect the effects of parenchymal tethering
on airway closing pressure; and (3) increasing transpulmonary
pressure [P tp(z)] in proportion to the extent of volume reduc-
tion. Regional and global RV, TLC, and RV/TLC predicted by the
model were then reassessed without changing model parameters
of unaffected alveoli.
ANALYSIS, DATA PRESENTATION, AND STATISTICS
Spirometry and lung volume measurements of participants in
studies NCT01051258, and NCT01181466 at baseline and follow-
ing treatment are presented as mean± standard deviation. The
effect of ELS treatment is summarized as absolute and percent-
age change from baseline. Statistical significance of changes from
baseline for continuous measures was assessed by paired t test.
Comparisons across 3 or more subgroups were performed by one
way analysis of variance. Assessment of statistical differences in
categorical outcome measures between groups was assessed by Chi
squared testing or Fisher’s exact test. Correlations were performed
using the method of Pearson. Statistical significance was based on
P values subject to correction for multiple comparisons using the
method of Bonferroni.
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RESULTS
BASELINE DEMOGRAPHICS, MEDICAL HISTORY, AND PULMONARY
FUNCTION
A total of 40 patients with homogeneous emphysema were enrolled
in studies NCT01051258 (n= 30) and NCT01181466 (n= 10).
Complete follow-up results are available for 38. Baseline character-
istics, including demographics, smoking history, body mass index
(BMI), GOLD classification, and medication use are summarized
in Table 1. Results are presented for the entire group, for the 18
NCT01051258 ULT patients, the 11 NCT01051258 LLT patients,
and the 9 NCT01181466 patients all of whom were treated in the
upper lobes.
Baseline characteristics were similar across all three subgroups
with respect to age, gender distribution, BMI, smoking history,
medication use, and disease severity. All patients were using
inhaled beta-agonist (31 short acting, 38 long acting) and anti-
cholinergic agent therapy (22 short acting, 38 long acting), 29
were using inhaled corticosteroids, 9 theophylline preparations, 5
oral corticosteroids, and 7 mucolytic agents. Seventeen patients
were receiving domiciliary oxygen therapy.
Baseline pulmonary function for the entire group (n= 38), and
for each subgroup is summarized in Table 2. Profiles are consis-
tent with advanced emphysema, showing severe airflow obstruc-
tion and hyperinflation. Comparison across the groups (ANOVA)
shows no significant differences in baseline pulmonary function.
SUMMARY OF OVERALL PHYSIOLOGICAL AND FUNCTIONAL
OUTCOMES
CT analysis confirmed the presence of homogeneous emphysema
among study patients. The HI for the 38 patients in this analysis
Table 1 | Summary of patient demographics and medical therapy.
All homogeneous patients ULT NCT01051258 LLT NCT01051258 ULT NCT01181466 Group Difference P value
Demographics
Number of patients 38 18 11 9 –
Gender (males) 21 11 4 6 0.315*
GOLD stage III/IV 22/16 10/8 7/4 5/4 0.901*
Smoking hx (pk yrs) 43.7 47.9 38.8 42.7 0.674**
Age (yrs) 62±8 64±7 58±9 63±7 0.275**
BMI (kg/m2) 25.2±3.9 25.3±4.1 24.9±3.7 25.1±4.6 0.345**
Medications
SABA 31 15 9 7 0.940*
LABA 38 18 11 9 1.0*
SAAC 22 9 7 6 0.349*
LAAC 38 18 11 9 1.0*
ICS 29 13 9 7 0.835*
Theophylline 9 4 3 2 0.950*
Oral steroids 5 3 1 1 0.824*
Oxygen use (any) 17 8 5 4 0.998*
*Comparison of ULP NCT01051258, LLT NCT 01051258, and ULT 01181466 by 1-way Pearson Chi-Square for >2 groups.
**Comparison of ULP NCT01051258, LLT NCT 01051258, and ULT 01181466 by 1-way ANOVA.
Table 2 | Baseline patient characteristics.
Baseline physiology
All patients (n=38) ULT NCT01051258 (n=18) LLT NCT01051258 (n=11) ULT NCT01181466 (n=9) Group difference
P value*
FEV1 0.93±0.30 L (32.1±8.3%
pred; range: 20.5–54.2%)
0.93±0.34 L (32.0±9.7%
pred; range: 20.5–54.2%)
0.94±0.25 L (32.3±5.4%
pred; range: 24.1–39.6%)
0.95±0.30 L (31.7±5.4%
pred; range: 20.1–39.0%)
0.985
FVC 2.53±0.75 L (66.0±14.5%
pred; range: 39.0–90.5%)
2.55±0.74 L (66.1±15.4%
pred; range: 39.0–90.5%)
2.50±0.80 L (65.9±13.4%
pred; range: 51.3–86.6%)
2.89±0.85 L (69.0±14.6%
pred; range: 42.6–94.3%)
0.456
RV 4.82±1.13 L (221.2±47.1%
pred; range: 141–308%)
4.82±1.06 L
(215.0±52.1% pred; range:
141–308%)
4.82±1.30 L
(232.9±35.0% pred;
range: 155–279%)
5.11±0.95 L
(217.5±44.2% pred; range:
146–305%)
0.747
TLC 7.43±1.25 L (127.2±16.4%
pred; range: 99–156%)
7.47±0.87 L (125.6±18.3%
pred; range: 99–156%)
7.36±1.82 L (130.1±12.3%
pred; range: 107–145%)
7.99±1.31 L (123.8±14.4%
pred; range: 99–143%)
0.653
*Comparison between ULP NCT01051258, LLT NCT 01051258, and ULT 01181466 by 1-way ANOVA.
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was (1.12± 0.26; Range 0.87–1.15). HI values for ULT patients in
study NCT01051258 (1.10± 0.22; Range 0.92–1.15), LLT patients
in study NCT01051258 (1.03± 0.34; Range 0.87–1.07), and
patients in study NCT01181466 (1.16± 0.34; Range 1.03–1.15)
were not significantly different (ANOVA; p= 0.445).
Quantitative CT analysis showed that LLT was associated
with a −217± 125 mL/treatment lobar volume reduction, and
a corresponding 35± 32 mL/treatment increase in upper lobe
volume. The net volume reduction following LLT measured
by CT analysis was −182± 121 mL/treatment. ULT was associ-
ated with a −265± 164 mL/treatment lobar volume reduction,
and corresponding 65± 17 mL/treatment increase in lower lobe
volume. The net volume reduction following ULT measured
by CT analysis was −201± 166 mL/treatment (p= 0.321; ULT
versus LLT).
The effects of ELS treatment on pulmonary function in
patients with advanced homogeneous emphysema are sum-
marized in Table 3. In study NCT01051258, unilateral treat-
ment was associated with improvements in FEV1 (+6.3± 16.5%;
p= 0.061), FVC (+7.5± 14.4%; p= 0.013), and RV/TLC
ratio (−4.5± 8.2%; p= 0.011). Patients who underwent ULT
(∆FEV1=+11.1± 14.7%, p= 0.005; ∆FVC=+9.8± 13.8%,
p= 0.008; and ∆RV/TLC=−5.4± 8.1, p= 0.011) experienced
significant improvements compared to baseline, while patients
who underwent LLT did not, despite equivalent lobar vol-
ume reduction. Reductions in overall gas trapping, mea-
sured physiologically as change from baseline in RV/TLC,
were greater for ULT (∆RV/TLC=−5.4± 8.1%) than LLT
(∆RV/TLC=−2.4± 8.6%) patients. Fourteen of 18 (78%)
patients receiving ULT experienced reductions in RV/TLC while
only 4 of 11 (36%) LLT patients experienced reductions (p= 0.07,
Fishers exact 2-tailed test).
Change from baseline in RV/TLC at 3 month follow-up corre-
lated significantly with the magnitude of lobar volume reduction
assessed by CT imaging in ULT patients (r = 0.54; p= 0.02), but
not in LLT patients (r = 0.09, p> 0.1), indicating that ULT vol-
ume reduction was effective in reducing gas trapping, while LLT
volume reduction was not.
Based upon these findings, all homogeneous emphy-
sema patients subsequently enrolled in the second study
(NCT01181466) received ULT. Results from this second study
confirm the effectiveness of upper lobe ELS treatment in homoge-
neous emphysema. Bilateral 4-site therapy at 3 month follow-up
was associated with improvements in spirometry and overall gas
trapping (Table 3).
MODEL SIMULATIONS OF UPPER VERSUS LOWER LOBE VOLUME
REDUCTION
Initial simulations were performed to validate the model by
matching predicted results to RV/TLC values reported for healthy
subjects (Anthonisen and Milic-Emili, 1966; Bryan et al., 1966;
Behrakis et al., 1983). Using representative normal values for
n (300× 106 alveoli), Vmax (20 microliters/alveolus), Vmin (4
microliters/alveolus), k (0.2), and P tm′ (0 cm H2O), model simula-
tions to predict RV/TLC values for alveoli as a function of vertical
distance from the lung apex were performed. Values were con-
sistent with data reported by Milic–Emili in healthy young males
(Figure 1A; Milic-Emili et al., 1966, 2007). A sensitivity analysis
to evaluate the effects of systematic changes in model parameters
was also performed. Varying parameters over a range considered
representative of “normal” (i.e.,±25% of values for healthy lung)
resulted in predicted RV/TLC values within the physiological range
(Figure 1B).
Simulations depicting advanced homogeneous emphysema are
shown in Figures 2A,B. To simulate emphysema, the number of
alveoli was set equal to 50% of normal (i.e., n= 150,000,000).
The remaining model parameters (Vmin/Vmax, k, and P tm′) were
also varied to simulate the effect of worsening emphysema.
Moderate to severe tissue destruction was represented by an
increase in Vmin/Vmax from 0.25 to 0.50. Loss in tissue elas-
ticity was represented by an increase in k from 0.2 to 0.3. An
increase in airway closing pressure due to loss of airway teth-
ering was represented by an increase in P tm′ from 0 to 1 cm
H2O. Assuming a normal active chest wall compliance curve (red
dashed line), the model predicts that these changes would cause
marked hyperinflation, gas trapping, and a decrease in lung elas-
tic recoil pressure as shown in Figure 2B. Such changes would be
expected to cause marked airflow limitation (Ingenito et al., 2001,
2003).
Using this model simulation of advanced homogeneous
emphysema as a starting point, additional simulations were then
performed to evaluate the physiological impact of upper lobe vol-
ume reduction and lower lobe volume reduction (Figure 3). The
combined effects of an increase in recoil pressure at total lung
inflation from 12.5 to 14 cm H2O, a shift in P tm′ from 1.0 to
0.5 cm H2O, and a decrease in cranio-caudal distance from apex
Table 3 | Summary of response to ELS therapy at week 12.
All homogeneous
patients (n=38)
ULT NCT01051258 (n=18) LLT NCT01051258 (n=11) ULT NCT01181466 (n=9) Group difference
P value*
∆FEV1 8.7±22.1%, P =0.026,
32% responders**
11.1±14.7%, P =0.005,
39% responders**
−4.4±15.8%, P =0.45, 9%
responders**
21.9±36.3%, P =0.159,
44% responders**
0.063
∆FVC 8.1±16.5%, P =0.008,
32% responders**
9.8±13.8%, P =0.008, 33%
responders**
2.4±15.3%, P =0.672, 22%
responders**
10.5±24.2%, P =0.293,
33% responders**
0.537
∆RV/TLC −5.3±8.2%, P =0.0008 −5.4±8.1%, P =0.012 −2.4±8.6%, P =0.448 −9.1±7.4%, P =0.030 0.331
*Comparison between ULP NCT01051258, LLT NCT 01051258, and ULT 01181466 by one-way.
**Responder definitions: ∆FEV1 and ∆FVC ≥12% increase from baseline.
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FIGURE 1 | (A) Shows model simulations depicting RV/TLC
ratios for individual alveoli in the healthy lung as a function of
distance from the lung base. (B) Shows how changes in key
model parameters (n, k, V min/V max, and P tm′ ) affect regional
RV/TLC values when varied ±25% as a group from reported
mean normal values.
to diaphragmatic dome from 35 to 33 cm while keeping k constant
at 0.3 is predicted to have the following physiological impact:
1. increase RV/TLC for all alveoli remaining in the upper lung
fields due to the distending effects of increasing P tp from 12.5
to 14 cm H2O (labeled “A”);
2. decreasing RV/TLC values of alveoli in the lower lung fields due
to the combined effects of gravity and a shift in P tm′ to a lower
value (labeled “B”);
3. causing a caudal shift in the location at which airway closure
occurs (labeled “C”).
The solid red line in Figure 3A shows how changes in transpul-
monary pressure and changes in the position of P tm′ in the
gravitation field resulting from volume reduction are predicted to
affect gas tapping (i.e., RV/TLC) of any single alveolus as a function
of its anatomic location. It does not, however, reflect how treat-
ment would affect overall gas trapping (RV/TLC) or lung recoil,
or how ULT versus LLT would differentially affect lung function.
This requires combining the impact of changes in transpulmonary
pressure and P tm′ with the effect of changing alveolar numbers
regionally as a result of volume reduction. The effect of volume
reduction treatment, in which either 25% of upper lobe alveoli or
the equivalent number (20%) of lower lobe alveoli are removed, is
shown in Figure 3B (ULT) and Figure 3C (LLT). In this example
ULT is associated with a decrease in overall RV/TLC from 0.68 to
0.63 (7.3% reduction) while LLT is associated with minimal change
(1.4%) despite a reduction in absolute RV from 5.8 to 5.6 L.
DISCUSSION
Conceptually, lung volume reduction therapy (LVRT) is a straight-
forward procedure that involves reducing the quantity of hyper-
inflated lung by eliminating damaged tissue. A simple but elegant
physiological model to explain the effects of LVRT on airflow lim-
itation in advanced emphysema was proposed over a decade ago
by Fessler and Permutt (1998). This model has since been val-
idated by clinical observations and physiological measurements
(Ingenito et al., 2001; Fessler et al., 2002). Despite its near universal
acceptance, the Fessler–Permutt model has at least one important
limitation: by considering volume reduction therapy throughout
the lung as equivalent, it fails to explain why patients who undergo
volume reduction therapy in the upper and lower lobes respond
differently.
The present study presents a novel perspective about the rela-
tive effects of upper versus lower lobe lung volume reduction on
gas trapping in emphysema. While consistent with the Fessler–
Permutt model, this analysis shows that gravitational effects can
significantly affect physiological responses to volume reduction by
attenuating the impact of LLT. Empirical observations from clin-
ical trial NCT01051258 involving endoscopic ELS treatment in
patients with homogeneous emphysema show that only patients
treated in the upper lobes consistently experienced physiological
benefit. This observation was then prospectively validated in a
second study (NCT01181466) in which all patients received ULT.
Although the number of patients in both studies was small, the
results were highly consistent.
Differences in physiology between ULT and LLT patients fol-
lowing ELS were not due to treatment failure in the LLT cohort.
Lobar volume reduction assessed by quantitative CT analysis was
similar in the two groups. The impact of ELS on gas trapping
assessed as change in RV/TLC measured by plethysmography, and
as change in FEV1 measured by spirometry, was substantially
different following ULT and LLT, however. Computer modeling
indicates this is due to two factors not previously recognized as
important when considering volume reduction therapy in this
population: (1) lung volume reduction, independent of where it
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FIGURE 2 | (A) Illustrates how changes in V min/V max (from 0.25 to 0.5), k (from
0.2 to 0.3), P tm′ (from 0 to 1 cm H2O) and n (from 300,000,000 to 150,000,000
alveoli) to simulate severe homogeneous emphysema affect regional alveolar
RV/TLC values as a function of distance from the lung base. (B) Illustrates
how these changes affect gas trapping and recoil pressure for the overall
lung. All simulations were performed assuming a 50% reduction in alveolar
number from baseline (i.e., decrease from 300,000,000 to 150,000,000) and
assume normal chest wall function (illustrated by red dashed line).
FIGURE 3 | (A) Shows simulations depicting regional RV/TLC values for
normal lung (black dashed line), severe homogeneous emphysema (blue
dashed line), and following lung volume reduction therapy in
homogeneous emphysema (red solid line) on regional RV/TLC values.
Lung volume reduction therapy in this example is modeled as decreasing
the overall size of the lung from 35 cm apex-to-base to 33 cm apex-to-base,
decreasing the total number of alveoli from 150,000,000 to 128,000,000,
and shifting airway closing pressure from 1 to 0.5 cm H2O. The increase in
P tp resulting from volume reduction therapy distends alveoli in the upper
lung fields, increasing regional RV/TLC ratios, labeled in this figure as
effect “A.” The decrease in P tm′ resulting from lung volume reduction
therapy causes a caudal shift in the position of at which airway closure
occurs, labeled in this figure as effect as “C.” Because lower lobe airways
remain opened to a greater extent following lung volume reduction, they
are able to deflate to a greater extent. This is labeled in this figure as effect
“B.” (B) Simulates the effects of a 25% decrease in the number of alveoli
in the upper lobes on overall gas trapping (RV/TLC) and recoil pressure. (C)
Shows a corresponding simulation for the equivalent lower lobe volume
reduction (elimination of the same number of alveoli). In this example,
upper lobe volume reduction is associated with a 6% decrease in overall
gas trapping, while lower lobe volume reduction is associated with a 1%
decrease in overall gas trapping.
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FIGURE 4 | Case summaries of two patients treated with ELS
illustrating the differential effects of upper (B) and lower (A) lobe lung
volume reduction.The two cases were closely matched with respect to
baseline patient characteristics, baseline physiology, and extent of lobar
volume reduction measured by CT imaging. However, responses to
treatment were quite different. Upper lobe treatment (B) was associated
with a substantial improvement in lung function. Lower lobe treatment
(A) had minimal beneficial effects on lung function. In each example, the
individual lobes have been shaded to better define lobar anatomy: the right
upper lobe is shaded red, the right middle lobe purple, the right lower lobe
yellow, the left upper lobe green, and the left lower lobe blue. Note that
physiology was measured in the upright position while CT imaging was
performed supine. The supine position is expected to alter gravitational
effects on CT measurements of lobar volume by underestimating upper
lobe volumes and overestimating lower lobe volumes by up to
approximately 10%.
is performed, increases the RV/TLC ratio of alveoli in the upper
lobes, but decreases RV/TLC ratio of alveoli in the lower lobes as
shown in Figure 3A; and (2) ULT removes alveoli with the high-
est RV/TLC values, while LLT removes alveoli with lower RV/TLC
values. As a result, ULT decreases both the number and mean
RV/TLC value of alveoli remaining within the lung. Conversely,
LLT decreases the number of remaining alveoli, but increases the
mean RV/TLC value of remaining alveoli.
The differential effect of ULT versus LLT will vary depend-
ing upon the baseline severity of gas trapping, the extent of
the volume reduction, and the effects of treatment on P tm′
and P tp. Modeling indicates, however, that ULT will always
be more effective than LLT in reducing RV/TLC in patients
with homogenous emphysema. Figure 4 summarizes two clinical
cases from study NCT01051258 that illustrate this point. These
patients had similar baseline demographics, physiologic charac-
teristics, and disease distribution patterns by CT imaging. One
was treated in the left lower lobe and one in the right upper
lobe based on baseline scintigraphy perfusion scanning showing
hypoperfusion in these regions. Despite similar lobar volume
reductions measured by quantitative CT imaging, overall physi-
ological responses were markedly different, consistent with model
predictions.
While these same physiological principles apply when consider-
ing LLT in patients with heterogeneous emphysema, the effects of
treatment can be quite different (McKenna et al., 1997; Gelb et al.,
1999; Chandra et al., 2010). The present analysis indicates that an
important step in achieving therapeutic lung volume reduction is
elimination of alveoli with “high RV/TLC” ratios, such that the
mean RV/TLC of alveoli that remain in the lung post treatment
is reduced. In heterogeneous emphysema, only the most damaged
regions of lung identified by CT imaging are targeted for treatment,
whether they reside in the upper or lower lobes. As a consequence,
the mean RV/TLC ratio of alveoli remaining post treatment should
always be reduced.
In summary, results from two small clinical trials show that
lower lobe volume reduction using ELS is less effective than upper
lobe volume reduction in patients with advanced homogeneous
www.frontiersin.org October 2012 | Volume 3 | Article 387 | 7
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emphysema. Physiological modeling indicates that this is due pri-
marily to differential effects of the procedure on upper versus
lower lobe alveoli. Shifts in P tp and P tm′ resulting from volume
reduction therapy increase RV/TLC of upper lobe alveoli, while
lowering RV/TLC of lower lobe alveoli. Removal of upper lobe
alveoli reduces the mean RV/TLC of the alveoli remaining in the
lung following therapy, while removal of lower lobe alveoli has the
opposite effect. As a consequence, the beneficial effects of tissue
resection following LLT are offset by an increase in gas trapped
within the alveoli that remain. These findings suggest that LVRT
for homogeneous emphysema should be limited to patients with
upper lobe target sites.
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